1
|
Zhang CW, Zhou B, Liu YC, Su LW, Meng J, Li SL, Wang XL. LINC00365 inhibited lung adenocarcinoma progression and glycolysis via sponging miR-429/KCTD12 axis. ENVIRONMENTAL TOXICOLOGY 2022; 37:1853-1866. [PMID: 35426242 DOI: 10.1002/tox.23532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 02/15/2022] [Accepted: 03/25/2022] [Indexed: 06/14/2023]
Abstract
This study researched the function of long non-coding RNA LINC00365 in lung adenocarcinoma (LAD) progression. LINC00365, miR-429, and KCTD12 expression in the LAD clinical tissues and cells were detcetd by qRT-PCR and Western blot. LINC00365, miR-429, and KCTD12 effects on H1975 cells malignant phenotype were detected by cell counting kit-8 assay, clone formation experiment, Transwell experiment, and glycolysis. Dual luciferase reporter gene assay and RNA pull-down assay were implemented. LINC00365 effect on H1975 cells in vivo growth was detected. LINC00365 was low expressed in the LAD patients and cells, associating with poor outcome. LINC00365 up-regulation attenuated H1975 cells proliferation, migration, invasion, glycolysis and in vivo growth. LINC00365 inhibited KCTD12 expression by sponging miR-429. miR-429 up-regulation and KCTD12 down-regulation partial reversed LINC00365 inhibition on H1975 cells malignant phenotype. Thus, LINC00365 inhibited LAD progression and glycolysis via targeting miR-429/KCTD12 axis. LINC00365 might be a potential candidate for LAD target treatment clinically.
Collapse
Affiliation(s)
- Cheng-Wei Zhang
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| | - Bin Zhou
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| | - Yan-Chao Liu
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| | - Li-Wei Su
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| | - Jie Meng
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| | - Shao-Lei Li
- Department of Thoracic Surgery II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
| | - Xue-Long Wang
- Department of Thoracic Surgery, Capital Medical University Electric Power Teaching Hospital, Beijing, China
| |
Collapse
|
2
|
Rizzini EL, Ghedini P, Cardano R, Bellarosa C, Morganti AG, Fanti S, Monari F. Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report. Mol Clin Oncol 2019; 11:63-66. [PMID: 31289680 DOI: 10.3892/mco.2019.1852] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 03/27/2019] [Indexed: 11/06/2022] Open
Abstract
Patients who undergo radium-223 treatment for metastatic castration-resistant prostate cancer (mCRPC) generally have a long history of androgen deprivation therapy and/or steroid therapy, which leads to bone loss and causes osteoporosis. Notably, Osteoporosis in combination with metastatic bone disease increases the risk of bone fracture. An 84-year-old man with multi-metastatic bone CRPC underwent six administrations of intravenous radium-223, which induced a good biochemical and clinical response. However, two months following the treatment, the patient reported acute pain localized to the lumbar spine mimicking bone progression disease and presented with stable prostate-specific antigen levels. A prostate-specific membrane antigen-positron emission tomography scan showed no tracer uptake in that site, whereas a magnetic resonance imaging scan and subsequent vertebral biopsy confirmed the absence of cancer progression and showed the presence of vertebral crushing of L4-L5, which was probably due to an osteoporotic process. The patient had never received bisphosphonate therapy and refused it during α-emitting therapy with radium-223. The osteoporotic process, in association with metastatic bone disease, more easily leads to bone fractures that have an important impact on performance status, quality of life and prognosis quoad vitam in patients with advanced prostate cancer. Use of bisphosphonates or anti-RANKL antibody appears to be effective in improving bone mineral density. Notably, patients with multi-metastatic bone disease who undergo radium-223 therapy should be treated in conjunction with anti-osteoporotic therapy (bisphosphonates or anti-RANKL antibody) and adequate calcium and vitamin D supplementation. Early recognition and differentiation of osteoporotic processes when determining the progression of cancer-associated bone disease is crucial in evaluating the response to radium-223 therapy and, consequently, for further therapeutic decision making.
Collapse
Affiliation(s)
- Elisa Lodi Rizzini
- Nuclear Medicine Unit, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy.,DIMES University of Bologna, I-40138 Bologna, Italy
| | - Pietro Ghedini
- Nuclear Medicine Unit, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy.,DIMES University of Bologna, I-40138 Bologna, Italy
| | - Raffaele Cardano
- DIMES University of Bologna, I-40138 Bologna, Italy.,Radiation Oncology Center, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy
| | - Chiara Bellarosa
- DIMES University of Bologna, I-40138 Bologna, Italy.,Radiation Oncology Center, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy
| | - Alessio Giuseppe Morganti
- DIMES University of Bologna, I-40138 Bologna, Italy.,Radiation Oncology Center, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy
| | - Stefano Fanti
- Nuclear Medicine Unit, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy.,DIMES University of Bologna, I-40138 Bologna, Italy
| | - Fabio Monari
- Radiation Oncology Center, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy
| |
Collapse
|
3
|
Li S, Zhao Y, Chen W, Yin L, Zhu J, Zhang H, Cai C, Li P, Huang L, Ma P. Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer. J Cancer 2018; 9:2659-2665. [PMID: 30087706 PMCID: PMC6072821 DOI: 10.7150/jca.25201] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 05/03/2018] [Indexed: 12/11/2022] Open
Abstract
Up-regulation of serum ephrinA2 is common in various malignancies and has been suggested as a potential biomarker for the diagnosis and prognosis of prostate cancer (PCa). However, the type of serum ephrinA2 expressed in PCa patients remains elusive. Furthermore, the level of exosomal ephrinA2 derived from serum is increased in patients with osteoporosis, a common complication of PCa patients undergoing androgen deprivation therapy. It is unknown whether exosomes derived from PCa patient serum contains ephrinA2. In this study, we explored the ephrinA2 expression in whole serum and tissues and identified the circulating exosomal ephrinA2 as a potential biomarker for PCa. Exosomes were isolated from patient sera by differential centrifugation and the presence of ephrinA2 was confirmed via electron microscopy and western blotting. The type of ephrinA2 in serum was evaluated by western blotting. The expression of serum ephrinA2 including secreted and cleaved ephrinA2 and exosomal ephrinA2 were detected by ELISA and western blotting. Compared with benign prostatic hyperplasia (BPH) and controls, the levels of whole serum ephrinA2 and exosomal ephrinA2 were significantly higher in PCa patients. Moreover, exosomal ephrinA2 expression was positively correlated with TNM staging and Gleason score of PCa patients. The diagnostic efficiency of exosomal ephrinA2 was superior to that of whole serum ephrinA2 and serum PSA in distinguishing PCa patients from those from BPH patents. Our study indicates that exosomal ephrinA2 has high potential as a biomarker for the presence of PCa and offers a new therapeutic target for this disease.
Collapse
Affiliation(s)
- Shibao Li
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China.,Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Yao Zhao
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Wenbai Chen
- Department of Nuclear Medicine Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Lingyu Yin
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Jie Zhu
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Haoliang Zhang
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Chenchen Cai
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Pengpeng Li
- Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - Lingyan Huang
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China
| | - Ping Ma
- Medical Technology Institute of Xuzhou Medical University, Xuzhou 221004, China.,Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| |
Collapse
|
4
|
Kirk PS, Borza T, Shahinian VB, Caram ME, Makarov DV, Shelton JB, Leppert JT, Blake RM, Davis JA, Hollenbeck BK, Sales A, Skolarus TA. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer. BJU Int 2018; 121:558-564. [PMID: 29124881 PMCID: PMC5878705 DOI: 10.1111/bju.14075] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVES To assess bone-density testing (BDT) use amongst prostate cancer survivors receiving androgen-deprivation therapy (ADT), and downstream implications for osteoporosis and fracture diagnoses, as well as pharmacological osteoporosis treatment in a national integrated delivery system. PATIENTS AND METHODS We identified 17 017 men with prostate cancer who received any ADT between 2005 and 2014 using the Veterans Health Administration cancer registry and administrative data. We identified claims for BDT within a 3-year period of ADT initiation. We then used multivariable regression to examine the association between BDT use and incident osteoporosis, fracture, and use of pharmacological treatment. RESULTS We found that a minority of patients received BDT (n = 2 502, 15%); however, the rate of testing increased to >20% by the end of the study period. Men receiving BDT were older at diagnosis and had higher-risk prostate cancer (both P < 0.001). Osteoporosis and fracture diagnoses, use of vitamin D ± calcium, and bisphosphonates were all more common in men who received BDT. After adjustment, BDT, and to a lesser degree ≥2 years of ADT, were both independently associated with incident osteoporosis, fracture, and osteoporosis treatment. CONCLUSIONS BDT is rare amongst patients with prostate cancer treated with ADT in this integrated delivery system. However, BDT was associated with substantially increased treatment of osteoporosis indicating an underappreciated burden of osteoporosis amongst prostate cancer survivors initiating ADT. Optimising BDT use and osteoporosis management in this at-risk population appears warranted.
Collapse
Affiliation(s)
- Peter S. Kirk
- Dow Division of Health Services Research, Department of Urology, University of Michigan Health System
| | - Tudor Borza
- Dow Division of Health Services Research, Department of Urology, University of Michigan Health System
| | - Vahakn B. Shahinian
- Division of Nephrology, Department of Internal Medicine, University of Michigan Health System
| | - Megan E.V. Caram
- Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan Health System
- VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System
| | - Danil V. Makarov
- Departments of Urology and Population Health, NYU Langone Medical Center
- VA New York Healthcare System, NY
| | | | - John T. Leppert
- Department of Urology, Stanford University School of Medicine
- VA Palo Alto Healthcare System, Palo Alto
| | - Ryan M. Blake
- Dow Division of Health Services Research, Department of Urology, University of Michigan Health System
| | - Jennifer A. Davis
- VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System
| | - Brent K. Hollenbeck
- Dow Division of Health Services Research, Department of Urology, University of Michigan Health System
| | - Anne Sales
- VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System
- Department of Learning Health Sciences, University of Michigan Medical School
| | - Ted A. Skolarus
- Dow Division of Health Services Research, Department of Urology, University of Michigan Health System
- VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System
| |
Collapse
|
5
|
Benabdelouahab Y, Muñoz-Moreno L, Frik M, de la Cueva-Alique I, El Amrani MA, Contel M, Bajo AM, Cuenca T, Royo E. Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands. Eur J Inorg Chem 2015; 2015:2295-2307. [PMID: 27175101 DOI: 10.1002/ejic.201500097] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The investigation of the hydrogen-bonding effect on the aggregation tendency of ruthenium compounds [(η6-p-cymene)Ru(κNHR,κNOH)Cl]Cl (R = Ph (1a), Bn (1b)) and [(η6-p-cymene)Ru(κ2NH(2-pic),κNOH)][PF6]2 (1c), [(η6-p-cymene)Ru(κNHBn,κNO)Cl] (2b) and [(η6-p-cymene)Ru(κNBn,κ2NO)] (3b), has been performed by means of concentration dependence 1H NMR chemical shifts and DOSY experiments. The synthesis and full characterization of new compounds 1c, [(η6-p-cymene)Ru(κNPh,κ2NO)] (3a) and 3b are also reported. The effect of the water soluble ruthenium complexes 1a-1c on cytotoxicity, cell adhesion and cell migration of the androgen-independent prostate cancer PC3 cells have been assessed by MTT, adhesion to type-I-collagen and recovery of monolayer wounds assays, respectively. Interactions of 1a-1c with DNA and human serum albumin have also been studied. Altogether, the properties reported herein suggest that ruthenium compounds 1a-1c have considerable potential as anticancer agents against advanced prostate cancer.
Collapse
Affiliation(s)
- Yosra Benabdelouahab
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Química, Biología y Ciencias Ambientales, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - Laura Muñoz-Moreno
- Department of Systems Biology, Faculty of Medicine and Health Sciences, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - Malgorzata Frik
- Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York, 11210, United States; Chemistry PhD Program, The Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States
| | - Isabel de la Cueva-Alique
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Química, Biología y Ciencias Ambientales, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - Mohammed Amin El Amrani
- Université Abdelmalek Essaâdi, Faculté des Sciences, Departement de Chimie- Laboratoire de Chimie Organique Appliquée. Mhannech II, B.P : 2121 Tétouan, Morocco
| | - María Contel
- Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, New York, 11210, United States; Chemistry PhD Program, The Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States
| | - Ana M Bajo
- Department of Systems Biology, Faculty of Medicine and Health Sciences, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - Tomás Cuenca
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Química, Biología y Ciencias Ambientales, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | - Eva Royo
- Departamento de Química Orgánica y Química Inorgánica, Facultad de Química, Biología y Ciencias Ambientales, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| |
Collapse
|
6
|
Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL, Holen I. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer 2014; 21:769-81. [PMID: 25052474 DOI: 10.1530/erc-14-0199] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Up to 90% of patients with castrate-resistant prostate cancer develop bone metastases, and the majority of these men have received androgen deprivation therapy known to cause bone loss. Whether this treatment-induced change to the bone microenvironment affects disseminated tumour cells, potentially stimulating development of bone metastasis, remains to be determined. The objective of this study was to use an in vivo model mimicking androgen ablation to establish the effects of this intervention on disseminated prostate cancer cells in bone. We mimicked the effects of androgen deprivation on bone metastasis by castrating 12-week-old BALB/c nude mice that had disseminated, hormone-insensitive PC3 prostate cancer cells present in the long bones. Castration caused increased bone resorption and loss of bone volume, compared with sham operation. In addition, castration triggered growth of disseminated PC3 cells to form bone metastasis in 70% of animals. In contrast, only 10% of sham-operated animals had detectable long bone tumours. Weekly administration of 100 μg/kg zoledronic acid (ZOL) prevented castration-induced tumour growth in bone and increased bone volume, but did not eliminate the disseminated tumour cells. ZOL had no effect on tumour growth in the sham-operated animals, despite causing a significant increase in bone volume. This is the first demonstration that, in a model of prostate cancer bone metastasis, mimicking androgen ablation results in growth of disseminated tumour cells in bone through osteoclast-mediated mechanisms. We provide the first biological evidence supporting the administration of ZOL to prostate cancer patients at the time of androgen ablation to prevent subsequent relapse in bone.
Collapse
Affiliation(s)
- Penelope D Ottewell
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Ning Wang
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Joshua Meek
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - C Anne Fowles
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Peter I Croucher
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Colby L Eaton
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Ingunn Holen
- Academic Unit of Clinical Oncology, Department of OncologyBone Biology, Department of Human Metabolism, Medical School, University of SheffieldBeech Hill Road, Sheffield S10 2RX, UKMusculoskeletal Medicine DivisionGarvan Institute of Medical Research, Sydney, New South Wales, Australia
| |
Collapse
|
7
|
Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. PATIENT-RELATED OUTCOME MEASURES 2014; 5:63-70. [PMID: 25045284 PMCID: PMC4094624 DOI: 10.2147/prom.s52788] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Androgen deprivation therapy (ADT) constitutes the first-line treatment for patients with locally advanced tumors, recurrent or metastatic disease. Given its widespread use, clinicians should be familiar with common side effects of this treatment. This review focuses on common side effects of ADT and available treatment options to control the side effects. Also, it briefly compares continuous ADT with other therapeutic approaches for androgen deprivation in prostate cancer patients. Similar to hormonal medications, newer non-hormonal therapeutic options including gabapentin and acupuncture have at best moderate effect in controlling hot flashes in patients on ADT. Supervised and/or home exercise programs significantly improve ADT-related fatigue, metabolic/cardiovascular side effects, and cognitive dysfunction. Denosumab, a human monoclonal antibody against RANK-L, is more effective than bisphosphonates in preventing skeletal-related events in patients with metastatic or castrate-resistant prostate cancer and unlike bisphosphonates, it can also reduce the risk of vertebral fractures in men receiving ADT for non-metastatic prostate cancer. Toremifene, a selective estrogen receptor inhibitor, has dual beneficial effects on ADT-related osteoporosis and metabolic dysfunction. Metformin coupled with lifestyle modification is also a well-tolerated treatment for metabolic changes during ADT. While producing similar oncological outcomes, intermittent ADT is associated with higher quality of life in patients under ADT by improving bone health, less metabolic and hematologic complications, and fewer hot flashes and sexual dysfunction events.
Collapse
Affiliation(s)
- Hamed Ahmadi
- Institute of Urology, University of Southern California, Los Angeles, CA, USA
| | - Siamak Daneshmand
- Institute of Urology, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|